Literature DB >> 17510631

Neuronal apoptosis and reversible motor deficit in dominant-negative GSK-3 conditional transgenic mice.

Raquel Gómez-Sintes1, Félix Hernández, Analía Bortolozzi, Francesc Artigas, Jesús Avila, Paola Zaratin, Jean Pierre Gotteland, José J Lucas.   

Abstract

Increased glycogen synthase kinase-3 (GSK-3) activity is believed to contribute to the etiology of chronic disorders like Alzheimer's disease and diabetes, thus supporting therapeutic potential of GSK-3 inhibitors. However, sustained GSK-3 inhibition might induce tumorigenesis through beta-catenin-APC dysregulation. Besides, sustained in vivo inhibition by genetic means (constitutive knock-out mice) revealed unexpected embryonic lethality due to massive hepatocyte apoptosis. Here, we have generated transgenic mice with conditional (tetracycline system) expression of dominant-negative-GSK-3 as an alternative genetic approach to predict the outcome of chronic GSK-3 inhibition, either per se, or in combination with mouse models of disease. By choosing a postnatal neuron-specific promoter, here we specifically address the neurological consequences. Tet/DN-GSK-3 mice showed increased neuronal apoptosis and impaired motor coordination. Interestingly, DN-GSK-3 expression shut-down restored normal GSK-3 activity and re-established normal incidence of apoptosis and motor coordination. These results reveal the importance of intact GSK-3 activity for adult neuron viability and physiology and warn of potential neurological toxicity of GSK-3 pharmacological inhibition beyond physiological levels. Interestingly, the reversibility data also suggest that unwanted side effects are likely to revert if excessive GSK-3 inhibition is halted.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17510631      PMCID: PMC1888681          DOI: 10.1038/sj.emboj.7601725

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  47 in total

Review 1.  Conditional control of gene expression in the mouse.

Authors:  M Lewandoski
Journal:  Nat Rev Genet       Date:  2001-10       Impact factor: 53.242

2.  Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion.

Authors:  K Matsuura; H Kabuto; H Makino; N Ogawa
Journal:  J Neurosci Methods       Date:  1997-04-25       Impact factor: 2.390

3.  Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3.

Authors:  Tobias Engel; Félix Hernández; Jesús Avila; José J Lucas
Journal:  J Neurosci       Date:  2006-05-10       Impact factor: 6.167

4.  Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation.

Authors:  K P Hoeflich; J Luo; E A Rubie; M S Tsao; O Jin; J R Woodgett
Journal:  Nature       Date:  2000-07-06       Impact factor: 49.962

5.  Role of glycogen synthase kinase-3beta in neuronal apoptosis induced by trophic withdrawal.

Authors:  M Hetman; J E Cavanaugh; D Kimelman; Z Xia
Journal:  J Neurosci       Date:  2000-04-01       Impact factor: 6.167

6.  Full motor recovery despite striatal neuron loss and formation of irreversible amyloid-like inclusions in a conditional mouse model of Huntington's disease.

Authors:  Miguel Díaz-Hernández; Jesús Torres-Peraza; Alejandro Salvatori-Abarca; María A Morán; Pilar Gómez-Ramos; Jordi Alberch; José J Lucas
Journal:  J Neurosci       Date:  2005-10-19       Impact factor: 6.167

7.  Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase.

Authors:  D P Hanger; K Hughes; J R Woodgett; J P Brion; B H Anderton
Journal:  Neurosci Lett       Date:  1992-11-23       Impact factor: 3.046

8.  GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides.

Authors:  Christopher J Phiel; Christina A Wilson; Virginia M-Y Lee; Peter S Klein
Journal:  Nature       Date:  2003-05-22       Impact factor: 49.962

9.  Role of glycogen synthase kinase 3 beta as a negative regulator of dorsoventral axis formation in Xenopus embryos.

Authors:  I Dominguez; K Itoh; S Y Sokol
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

Review 10.  Role of tau protein in both physiological and pathological conditions.

Authors:  Jesus Avila; Jose J Lucas; Mar Perez; Felix Hernandez
Journal:  Physiol Rev       Date:  2004-04       Impact factor: 37.312

View more
  29 in total

1.  GSK-3β dysregulation contributes to parkinson's-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and α-synuclein.

Authors:  J J Credle; J L George; J Wills; V Duka; K Shah; Y-C Lee; O Rodriguez; T Simkins; M Winter; D Moechars; T Steckler; J Goudreau; D I Finkelstein; A Sidhu
Journal:  Cell Death Differ       Date:  2014-11-14       Impact factor: 15.828

2.  NFAT/Fas signaling mediates the neuronal apoptosis and motor side effects of GSK-3 inhibition in a mouse model of lithium therapy.

Authors:  Raquel Gómez-Sintes; José J Lucas
Journal:  J Clin Invest       Date:  2010-06-07       Impact factor: 14.808

3.  Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease.

Authors:  David E Hurtado; Laura Molina-Porcel; Jenna C Carroll; Caryn Macdonald; Awo K Aboagye; John Q Trojanowski; Virginia M-Y Lee
Journal:  J Neurosci       Date:  2012-05-23       Impact factor: 6.167

4.  Lithium suppression of tau induces brain iron accumulation and neurodegeneration.

Authors:  P Lei; S Ayton; A T Appukuttan; S Moon; J A Duce; I Volitakis; R Cherny; S J Wood; M Greenough; G Berger; C Pantelis; P McGorry; A Yung; D I Finkelstein; A I Bush
Journal:  Mol Psychiatry       Date:  2016-07-12       Impact factor: 15.992

5.  GSK3β expression and phosphorylation during neuronal maturation in the rat dorsal root ganglion.

Authors:  Wenjie Tang; Ning Han; Yangzhou Liu; Zengchun Li; Youzhen Wei
Journal:  Int J Clin Exp Med       Date:  2015-04-15

6.  Tau Ser262 phosphorylation is critical for Abeta42-induced tau toxicity in a transgenic Drosophila model of Alzheimer's disease.

Authors:  Koichi Iijima; Anthony Gatt; Kanae Iijima-Ando
Journal:  Hum Mol Genet       Date:  2010-05-12       Impact factor: 6.150

Review 7.  Why pleiotropic interventions are needed for Alzheimer's disease.

Authors:  Sally A Frautschy; Greg M Cole
Journal:  Mol Neurobiol       Date:  2010-05-02       Impact factor: 5.590

Review 8.  Behind the curtain of tauopathy: a show of multiple players orchestrating tau toxicity.

Authors:  Yunpeng Huang; Zhihao Wu; Bing Zhou
Journal:  Cell Mol Life Sci       Date:  2015-09-24       Impact factor: 9.261

9.  An essential role for Frizzled5 in neuronal survival in the parafascicular nucleus of the thalamus.

Authors:  Chunqiao Liu; Yanshu Wang; Philip M Smallwood; Jeremy Nathans
Journal:  J Neurosci       Date:  2008-05-28       Impact factor: 6.167

10.  GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals.

Authors:  Shuxin Hu; Aynun N Begum; Mychica R Jones; Mike S Oh; Walter K Beech; Beverly Hudspeth Beech; Fusheng Yang; Pingping Chen; Oliver J Ubeda; Peter C Kim; Peter Davies; Qiulan Ma; Greg M Cole; Sally A Frautschy
Journal:  Neurobiol Dis       Date:  2008-11-05       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.